RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; H.R. 1672, Maintaining Investments in New Innovation Act; P.L. 119-21; U.S. Competitiveness
Literal federal measure citations: H.R. 1672
2026 · 2nd Quarter (Apr 1 - June 30)
ALNYLAM PHARMACEUTICALS, INC.
Filed by SPLITOAK STRATEGIES LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 20, 2026
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- SPLITOAK STRATEGIES LLC
- Filing UUID
- bd04d7de-a91d-4be5-8350-431a97162b04
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.